Atlas Trials

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Clinical trial NCT06110793 · RECRUITING

Trial details

NCT number
NCT06110793
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2023-12-29
Primary completion
2027-11-01
Enrollment
56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.